Translational Oncology最新文献

{"title":"Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis","authors":"Michael G. White ,&nbsp;Reed I. Ayabe ,&nbsp;Mohammad A. Zeineddine ,&nbsp;Fadl A. Zeineddine ,&nbsp;Abdelrahman M.G. Yousef ,&nbsp;Mahmoud Yousef ,&nbsp;Norman J. Galbraith ,&nbsp;J․Bryan Iorgulescu ,&nbsp;Christopher Scally ,&nbsp;Keith Fournier ,&nbsp;Timothy E. Newhook ,&nbsp;Nancy Y. You ,&nbsp;Jason Willis ,&nbsp;Scott Kopetz ,&nbsp;George J. Chang ,&nbsp;John Paul Shen ,&nbsp;Abhineet Uppal","doi":"10.1016/j.tranon.2025.102379","DOIUrl":"10.1016/j.tranon.2025.102379","url":null,"abstract":"<div><div>Colorectal peritoneal metastases (CPM) are the third most common site of metastatic spread of colorectal cancer and are associated with worse survival than other sites of metastatic disease. In recent years tumoral circulating tumoral DNA (ctDNA) mutational status has been increasingly utilized in clinical decision making for metastatic colorectal cancer patients despite its utility in CPM being poorly understood. Here we describe standard of care performed mutational profiles and associated outcomes for unresectable CPM patients, with a contextual comparison to 160 unresected colorectal liver metastases (CLM) patients. Of 508 patients, 288 (57 %) had CPM alone and 220 (43 %) had CPM with extraperitoneal metastases. Patients with synchronous CPM and CLM had worse overall survival (HR 1.67 [95 %CI 1.26–2.22]). Mutations in ctDNA were noted in 110/145 (75.9 %) of CPM patients, with mutations in <em>KRAS</em> or <em>PIK3CA</em> ctDNA being associated with worse survival. Importantly, the association between tumoral mutational profile and survival differed by site of metastatic disease. The prognostic significance of specific mutations, particularly <em>BRAF</em> and <em>KRAS</em>, differs between patients with CPM and CLM, and supports the distinct biology of these metastatic sites and the importance of tissue and circulating genomic profiling to risk-stratify these patients according to site of metastasis.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"55 ","pages":"Article 102379"},"PeriodicalIF":5.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occult ovarian high-grade serous carcinoma presenting as isolated inguinal lymph node metastasis: A case report and literature review","authors":"XiaoJing Guan,&nbsp;Zhi Ma,&nbsp;JianHua Yang","doi":"10.1016/j.tranon.2025.102371","DOIUrl":"10.1016/j.tranon.2025.102371","url":null,"abstract":"<div><div>Superficial inguinal lymph node (SILN) metastasis is rare in ovarian cancer, particularly as an isolated presentation without peritoneal dissemination. Here we report a case of solitary SILN metastasis in a patient with high-grade serous carcinoma of ovarian cancer and review previously reported cases from literature. A 58-year-old woman presented with isolated right groin swelling (approximately 4 cm), excisional biopsy suggested ovarian origin but comprehensive imaging and laparoscopy failed to identify a primary intra-abdominal tumor, and postoperative pathology confirmed no evidence of ovarian involvement. Following multidisciplinary consultation, the patient received six cycles of paclitaxel (175 mg/m²) plus carboplatin (AUC-5) chemotherapy (21-day intervals). Remarkably, five years post-treatment, she remains disease-free, highlighting the potential for favorable outcomes even in rare metastatic presentations. This case demonstrates that ovarian cancer is not a disease confined to the intra-peritoneal cavity; SILN metastasis might occur in rare cases possibly via lymphatic and/or hematogenous spread route under specific circumstances. Further investigations related to risk factors and metastatic patterns are warranted to explore the mechanisms and clinical implications of isolated SILN metastasis in ovarian cancer.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"55 ","pages":"Article 102371"},"PeriodicalIF":5.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yi Shen Tiao Gan decoction alleviates aromatase inhibitor–related bone loss by promoting H-type vessel formation","authors":"Meiling Chu ,&nbsp;Yan Zhang ,&nbsp;Meina Ye ,&nbsp;Yulian Yin ,&nbsp;Hongfeng Chen","doi":"10.1016/j.tranon.2025.102377","DOIUrl":"10.1016/j.tranon.2025.102377","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Aromatase inhibitors (AIs) are the main drugs used in the endocrine therapy of breast cancer. Given the continuous reduction in their estrogen levels, the quality of life and medication compliance of patients with osteopenia and osteoporosis, also called aromatase inhibitor–associated bone loss (AIBL), are seriously affected. &lt;em&gt;Yi Shen Tiao Gan&lt;/em&gt; decoction (YSTG) is a traditional Chinese medicine prescription that is widely used in China to treat AIBL. Clinical studies have shown that YSTG can effectively decelerate AIBL. However, the molecular mechanisms underlying the effects of YSTG on AIBL remain unclear. In contrast to previous studies on the mechanism of AIBL, which focused on the relationship between estrogen and osteoclasts, this study adopts a novel perspective by focusing on H-type blood vessels and Slit guidance ligand 3 (SLIT3). H-type vessels, a recently identified subtype of capillaries, are predominantly located in the epiphysis and endosteum of long bones. These vessels play a crucial role in mediating the coupling of angiogenesis and osteogenesis within the bone microenvironment, with their abundance serving as a sensitive indicator of bone mass. Notably, SLIT3, a proangiogenic factor secreted by osteoblasts, is actively involved in the regulation of H-type vessel formation and bone formation processes. Here, we used the inoculation and resection of breast cancer xenografts, bilateral ovaritectomy (OVX), and gavage of letrozole (Femara) to construct a suitable AIBL animal model, which was verified by ELISA, microcomputed tomography (micro-CT), hematoxylin and eosin staining, and OCN and tartrate-resistant acid phosphatase (TRAP) immunohistochemical staining. H-type vessels were used as the entry point to study the mechanism of AIBL on the basis of the AIBL animal model. Among mice, the nude mice in the mastectomy (MX)+OVX+Le group showed the most severe bone loss after breast cancer cell implantation and resection, OVX, and Le gavage. Therefore, this group was suitable as an animal model of breast cancer AIBL than other groups. The animal experiment on the mechanism of YSTG in improving bone loss found that YSTG treatment significantly reduced the contents of C-terminal telopeptide of type I collagen, procollagen type I N-terminal propeptide, and growth hormone and increased those of serum estradiol and SLIT3. Micro-CT quantitative detection showed that after YSTG treatment, bone BMD, BV:TV, and Tb.N increased. The HE staining of bone tissue revealed that the thickness and number of trabecular bone and the number of cells in the cartilage layer of the femur remarkably increased after YSTG treatment. YSTG reduced TRAP content near the growth plate of the femoral metaphysis. YSTG significantly increased the OCN content at the margin of the trabecular bone in the metaphysis of the femur. Immunofluorescence results confirmed that YSTG could increase the amount of H-type vascular cells in bone. WB analysis confirmed tha","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"55 ","pages":"Article 102377"},"PeriodicalIF":5.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143739751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the cellular and molecular heterogeneity in colorectal cancer through the use of single-cell RNA sequencing","authors":"Yuemiao Chen,&nbsp;Jian Huang,&nbsp;Yufang Fan,&nbsp;Lifeng Huang,&nbsp;Xiaoping Cai","doi":"10.1016/j.tranon.2025.102374","DOIUrl":"10.1016/j.tranon.2025.102374","url":null,"abstract":"<div><div>The very prevalent nature, genetic variability, and intricate tumor microenvironment (TUME) of colorectal cancer (COREC) are its defining features. In order to better understand the molecular and cellular make-up of COREC, this work used single-cell RNA sequencing (SRNAS) to isolate and characterize important cell types as well as their interactions within the TUME. Our analysis of 51,204 cells yielded six distinct types: epithelial, fibroblast, endothelial, T&amp;NK, B, and myeloid. C3 B cells were shown to be the most active in immunological regulation, according to chemokine signaling study, which was one of seven clusters of B cells that were thoroughly subtyped. The examination of copy number variation (CONUV) revealed a great deal of genetic variability, especially in epithelial cells. We traced the activity of three key transcription factor clusters (M1, M2, and M3) across all B cell subtypes using transcription factor analysis. We created a predictive model that correctly sorts patients according to survival results by using marker genes from C3 B cells. In addition, the relationship between genetic changes and the immune system was better understood by tumor mutational burden (TUMUB) and immune infiltration studies. Our research sheds light on the genetic complexity and cellular variety of COREC, which in turn opens up new possibilities for targeted treatments and individualized approaches to patient care.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"55 ","pages":"Article 102374"},"PeriodicalIF":5.0,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143739906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer","authors":"Razia Rahman ,&nbsp;Luke A. Selth","doi":"10.1016/j.tranon.2025.102378","DOIUrl":"10.1016/j.tranon.2025.102378","url":null,"abstract":"<div><div>Transcriptional control of gene expression is fundamental to all cellular processes. Conversely, transcriptional dysregulation is a hallmark of cancer. While this hallmark is a key driver of all malignancy-related process, it also represents a vulnerability that can be exploited therapeutically. Prostate cancer is a prime example of this phenomenon: it is characterised by aberrant transcription and treated with drugs that influence transcriptional pathways. Indeed, the primary oncogenic driver and therapeutic target of prostate cancer, the androgen receptor (AR), is a transcription factor. Moreover, a plethora of other transcriptional regulators, including transcriptional cyclin-dependent kinases (CDK7, CDK8 and CDK9), MYC and Bromodomain-containing protein 4 (BRD4), play prominent roles in disease progression. In this review, we focus on the roles of transcriptional CDKs in prostate cancer growth, metastasis and therapy resistance and discuss their interplay with AR, MYC and BRD4. Additionally, we explore recent advances in the therapeutic targeting of transcriptional CDKs and propose how these strategies could be effectively harnessed for the treatment of prostate cancer.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"55 ","pages":"Article 102378"},"PeriodicalIF":5.0,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of transition metal content in glioblastoma reveals association between iron and survival","authors":"Ganesh Shenoy ,&nbsp;Aurosman Sahu ,&nbsp;Madison Kuhn ,&nbsp;Vladimir Khristov ,&nbsp;Madison Heebner ,&nbsp;Hannah Wilding ,&nbsp;Taylor Clegg ,&nbsp;Debarati Bhanja ,&nbsp;Quinn Wade ,&nbsp;Laura J. Liermann ,&nbsp;Dongxiang Wang ,&nbsp;Nataliya Smith ,&nbsp;Gabriela Remite-Berthet ,&nbsp;Chachrit Khunsriraksakul ,&nbsp;Kondaiah Palsa ,&nbsp;Becky Slagle-Webb ,&nbsp;Alireza Mansouri ,&nbsp;Brad E. Zacharia ,&nbsp;Elizabeth A. Proctor ,&nbsp;James R. Connor","doi":"10.1016/j.tranon.2025.102376","DOIUrl":"10.1016/j.tranon.2025.102376","url":null,"abstract":"<div><h3>Introduction</h3><div>Little is known about the role of transition metals in glioblastoma progression. Here we investigated whether transition metal content is associated with glioblastoma outcomes.</div></div><div><h3>Methods</h3><div>Tumor samples were obtained from 37 newly diagnosed patients with glioblastoma, 21 of which had matched plasma. Iron, zinc, manganese, and copper content in those samples was quantified via inductively-coupled mass spectrometry or atomic emission spectrometry, and subsequently analyzed for associations with overall survival. Multiplexed immune profiling was performed to determine whether transition metal content was associated with altered cytokine profiles.</div></div><div><h3>Results</h3><div>Higher plasma iron levels were strongly associated with prolonged survival (Kaplan-Meier analysis: 30.15 months vs. 12.43 months, P = 0.0036; Multivariate Cox regression analysis: HR: 0.79 [0.64 – 0.97], P = 0.03). Zinc, manganese, and copper concentration in plasma or tumor and iron in tumor were not significantly associated with overall survival. Immune profiling of plasma and tumor samples revealed that plasma iron correlated with plasma IFN-β concentration (R = 0.63, P = 0.0057) in patients with glioblastoma. No correlation of plasma iron and IFN-β was observed in age- and sex- matched healthy individuals (R = -0.15, P = 0.153). Plasma transition metal concentration did not correlate with tumor transition metal concentration. Within tumors, manganese and zinc were correlated (R = 0.52, P = 0.0048) as well as copper and zinc (R = 0.36, P = 0.038).</div></div><div><h3>Conclusions</h3><div>Plasma iron is associated with survival in glioblastoma patients and may serve as a prognostic marker. The mechanisms underlying this association require further study.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"55 ","pages":"Article 102376"},"PeriodicalIF":5.0,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143739750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulatory role of CD177+ neutrophils in BMP signaling pathway and its implications for inflammatory bowel disease, sepsis, and intestinal tumors","authors":"Lin Yu ,&nbsp;Haoyue Zhang ,&nbsp;Ling Jia ,&nbsp;Detian Lai ,&nbsp;Lina Jia ,&nbsp;Qingzhu Li ,&nbsp;Enwei Guo ,&nbsp;Feng Yang ,&nbsp;Bingyu Zhang ,&nbsp;Qiancheng Luo","doi":"10.1016/j.tranon.2025.102336","DOIUrl":"10.1016/j.tranon.2025.102336","url":null,"abstract":"<div><h3>Objectives</h3><div>Inflammatory bowel disease (IBD), sepsis, and intestinal tumors are major health threats. This study aimed to explore the regulatory role of CD177+ neutrophils in the BMP signaling pathway and its impact on the onset, progression, and treatment of these diseases.</div></div><div><h3>Methods</h3><div>Gene expression data from the Gene Expression Omnibus (GEO) database for IBD and sepsis were retrieved. Bioinformatics methods like background correction, normalization, and differential expression analysis were used. Weighted gene co-expression network analysis (WGCNA), gene functional enrichment analysis, pan-cancer analysis, single-cell analysis, and in vitro experiments including Caco-2 cell culture, cell proliferation assay (CCK-8), flow cytometry apoptosis analysis, quantitative real-time PCR (qRT-PCR), and plate colony formation assay were performed.</div></div><div><h3>Results</h3><div>Key genes associated with IBD and sepsis, such as BMP2, BMP4, BMP6, BMP8A, and CD177, were identified. WGCNA in sepsis found two significant modules related to key clinical outcomes. Core gene screening revealed seven shared genes between IBD and sepsis, and enrichment analysis showed involvement in important biological processes and pathways. Pan-cancer analysis showed diverse gene expression patterns and correlations with immune dynamics. Single-cell transcriptomics provided insights into the tumor microenvironment. In vitro experiments demonstrated that CD177 knockdown affected BMP signaling pathway-related gene expression, ROS production, apoptosis, and cell proliferation.</div></div><div><h3>Conclusion</h3><div>CD177+ neutrophils play a crucial role in regulating the BMP signaling pathway in IBD, sepsis, and intestinal tumors. These findings offer potential therapeutic targets, but further clinical validation is required to translate them into effective treatment strategies.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"55 ","pages":"Article 102336"},"PeriodicalIF":5.0,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PRMT5 inhibitors: Therapeutic potential in pancreatic cancer","authors":"Carolin Schneider ,&nbsp;Valentina Spielmann ,&nbsp;Christian J. Braun ,&nbsp;Günter Schneider","doi":"10.1016/j.tranon.2025.102366","DOIUrl":"10.1016/j.tranon.2025.102366","url":null,"abstract":"<div><div>Pancreatic ductal adenocarcinoma (PDAC) is predominantly driven by mutations in the Kirsten rat sarcoma virus (KRAS) oncogene. Due to the pivotal role of KRAS in PDAC pathogenesis, KRAS inhibitors (KRASi) have recently demonstrated initial signs of clinical efficacy. However, considering currently documented response rates and the resistance development to KRASi, additional targeted therapies are needed. In this context, we provide a summary of recent preclinical and clinical findings on protein arginine methyltransferase 5 (PRMT5) inhibitors (PRMT5i) and their implications for PDAC. PRMT5 has been linked to key oncogenic processes, including epithelial-mesenchymal transition (EMT), MYC and Hippo signaling pathways, glycolysis, and therapy resistance. With further advancements and optimization of PRMT5i-based therapies, these inhibitors hold significant potential as therapeutic agents for PDAC treatment. Therefore, we synthesize the current understanding of PRMT5i and highlight promising directions for future developments in PDAC.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"55 ","pages":"Article 102366"},"PeriodicalIF":5.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143715293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNA profiling reveals potential biomarkers for the early transformation of endometriosis towards endometriosis-correlated ovarian cancer","authors":"Gloria Ravegnini ,&nbsp;Camelia Alexandra Coadă ,&nbsp;Giulia Mantovani ,&nbsp;Antonio De Leo ,&nbsp;Dario de Biase ,&nbsp;Alessia Costantino ,&nbsp;Francesca Gorini ,&nbsp;Giulia Dondi ,&nbsp;Stella Di Costanzo ,&nbsp;Francesco Mezzapesa ,&nbsp;Federico Manuel Giorgi ,&nbsp;Giovanni Tallini ,&nbsp;Sabrina Angelini ,&nbsp;Annalisa Astolfi ,&nbsp;Lidia Strigari ,&nbsp;Pierandrea De Iaco ,&nbsp;Anna Myriam Perrone","doi":"10.1016/j.tranon.2025.102367","DOIUrl":"10.1016/j.tranon.2025.102367","url":null,"abstract":"<div><h3>Background</h3><div>Endometriosis (EMS) is a chronic, gynecological condition affecting 6–10 % of reproductive-age women. While these lesions are benign, ovarian EMS presents cancer-like features, and can progress to endometriosis-correlated ovarian cancer (ECOC) through a multistep process. Given the regulatory role of miRNAs in gene expression and biological pathways, we aimed to identify miRNAs associated with the malignant transformation of ovarian EMS, which could serve as a potential diagnostic tool for the early identification of such patients.</div></div><div><h3>Methods</h3><div>Global miRNA profiling was performed in 8 patients with benign ovarian EMS (EMS-b) and 29 patients with ECOC. Differential expression analysis (DEA) of miRNAs between EMS-b, EMS tissues from patients with ECOC (EMS-k) and ECOC tissues was performed. Receiver Operating Characteristic (ROC) curves were built to evaluate the binary classification performance of significant miRNAs.</div></div><div><h3>Results</h3><div>Comparison between EMS-b and EMS-k revealed 13 significantly deregulated miRNAs. Furthermore, when comparing ECOC and EMS-b, we observed significant deregulation of 181 miRNAs. ROC analysis revealed a panel of seven upregulated miRNAs with accuracies above 0.7 in identifying EMS-k and EMS-b. Notably, four miRNAs (hsa-miR-200a-3p, hsa-miR-141–3p, hsa-miR-183–5p, hsa-miR-10a-5p) were consistently upregulated in both EMS-k and ECOC tissues, achieving accuracies above 0.77 in distinguishing between EMS-k and EMS-b. When used to distinguish between EMS-b and ECOC tissues, these miRNAs showed accuracies even higher, above 0.94. Specifically, hsa-miR-183–5p had an accuracy of 1, hsa-miR-200a-3p and hsa-miR-141–3p of 0.97, while hsa-miR-10a-5p of 0.95.</div></div><div><h3>Conclusions</h3><div>Our study identified a panel of miRNA biomarkers that may serve as potential candidates for the early detection of ECOC in patients previously diagnosed with ovarian EMS.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"55 ","pages":"Article 102367"},"PeriodicalIF":5.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Fam198b as a novel biomarker for gastric cancer and a potential therapeutic target to prevent tumor cell proliferation dysregulation” [Translational Oncology 39 (2024) 101824]","authors":"Bangquan Chen ,&nbsp;Maladho Tanta Diallo ,&nbsp;Yue Ma ,&nbsp;Wenhao Yu ,&nbsp;Qing Yao ,&nbsp;Shuyang Gao ,&nbsp;Yantao Yu ,&nbsp;Qiannan Sun ,&nbsp;Yong Wang ,&nbsp;Jun Ren ,&nbsp;Daorong Wang","doi":"10.1016/j.tranon.2025.102297","DOIUrl":"10.1016/j.tranon.2025.102297","url":null,"abstract":"","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"55 ","pages":"Article 102297"},"PeriodicalIF":5.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}